Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.

5-year RFS was 88% vs 87% (difference 1.1%, 95% CI -5.8% to 8.0%). 5-year OS was 93.8% vs 93.3% (HR 1.05, 95% CI 0.47-2.37; P=0.887). In treated ctDNA-positive patients, end-of-treatment clearance occurred in 35/40 (87.5%); 5-year RFS was 85.2% with clearance vs 20.0% with persistence (HR 15.4, P<0.001). Higher post-surgery mutant tumor molecules (>=0.38 MTM/mL) were associated with lower clearance and worse RFS.

ASCO Annual Meeting 2024PubMed 40055522